FY2025 Earnings Forecast for XFOR Issued By HC Wainwright

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Stock analysts at HC Wainwright upped their FY2025 EPS estimates for shares of X4 Pharmaceuticals in a research note issued on Monday, November 10th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($2.26) per share for the year, up from their previous forecast of ($2.48). HC Wainwright has a “Buy” rating and a $3.50 price target on the stock. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.68) per share. HC Wainwright also issued estimates for X4 Pharmaceuticals’ Q4 2025 earnings at ($0.28) EPS, Q1 2026 earnings at ($0.27) EPS, Q2 2026 earnings at ($0.26) EPS, Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.26) EPS, FY2026 earnings at ($1.05) EPS, FY2027 earnings at ($0.84) EPS and FY2028 earnings at ($0.33) EPS.

Several other analysts have also recently weighed in on XFOR. Weiss Ratings reissued a “sell (e+)” rating on shares of X4 Pharmaceuticals in a report on Wednesday, October 8th. Stifel Nicolaus set a $7.50 target price on shares of X4 Pharmaceuticals in a research report on Wednesday, November 5th. Finally, Zacks Research raised X4 Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, October 21st. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, X4 Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $33.67.

X4 Pharmaceuticals Price Performance

X4 Pharmaceuticals stock opened at $3.53 on Wednesday. The business’s 50-day simple moving average is $3.40 and its 200 day simple moving average is $2.98. The stock has a market cap of $40.28 million, a price-to-earnings ratio of -0.35 and a beta of 0.51. X4 Pharmaceuticals has a 12-month low of $1.35 and a 12-month high of $26.83. The company has a quick ratio of 5.48, a current ratio of 5.65 and a debt-to-equity ratio of 1.23.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its earnings results on Wednesday, November 5th. The company reported ($0.69) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.10. The company had revenue of $1.77 million during the quarter, compared to analysts’ expectations of $2.05 million. X4 Pharmaceuticals had a negative return on equity of 343.67% and a negative net margin of 279.86%.

Insider Transactions at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, Chairman Adam R. Craig purchased 86,206 shares of the stock in a transaction on Thursday, October 23rd. The stock was bought at an average cost of $2.90 per share, for a total transaction of $249,997.40. Following the completion of the acquisition, the chairman directly owned 376,087 shares of the company’s stock, valued at $1,090,652.30. The trade was a 29.74% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.15% of the company’s stock.

Institutional Trading of X4 Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers boosted its holdings in shares of X4 Pharmaceuticals by 5.4% in the first quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock valued at $44,000 after buying an additional 9,690 shares during the period. Bank of America Corp DE boosted its position in X4 Pharmaceuticals by 20.3% during the 4th quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock worth $98,000 after acquiring an additional 22,485 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of X4 Pharmaceuticals by 9.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 481,528 shares of the company’s stock worth $114,000 after purchasing an additional 43,320 shares in the last quarter. Jane Street Group LLC increased its stake in X4 Pharmaceuticals by 112.5% in the 2nd quarter. Jane Street Group LLC now owns 97,344 shares of the company’s stock valued at $185,000 after buying an additional 51,544 shares during the last quarter. Finally, Palumbo Wealth Management LLC acquired a new position in shares of X4 Pharmaceuticals during the 3rd quarter worth about $326,000. 72.03% of the stock is currently owned by institutional investors and hedge funds.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.